Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study.
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNaestved Hospital
About this trial
Oncological treatment of patients with disseminated non-small cell lung cancer (NSCLC) is depending on the status of programmed death-ligand 1 (PD-L1), anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR), so called oncodrivers. These can be measured in pleural fluid, but the prevalence is uncertain. In a prospective study, the research team aim to measure PD-L1, ALK and EGFR in patients with pleural fluid cytology positive for NSCLC to report the prevalence. Also, the study will investigate if the chance of obtaining oncodriver status is depending on the volume analysed and how the lack of oncodrivers influence the following work-up.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Pleural effusion known or suspected of association with NSCLC (pleural fluid cytology positive for cells from NSCLC)
Patients must be able to give informed consent
Disqualifiers
Full oncodriver status measured in any pleural fluid in current work-up
Inability to understand written or spoken Danish.
Trial design
Treatments tested in this trial
- meassurement of PD-L1, ALK, EGFR
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov